Chapter 5 Infections

Size: px
Start display at page:

Download "Chapter 5 Infections"

Transcription

1 Chapter 5 page number 1 Chapter 5 Infections First line drugs Drugs recommended in both primary and secondary care. Second line drugs Alternatives (often in specific conditions) in both primary and secondary care. Specialist initiated drugs Secondary care, authorised independent prescribers or GPs with special interest initiation. Suitable for continuation by primary care. Shared care agreements may be applicable. Secondary care only drugs Drugs only suitable for secondary care use and initiated by appropriate team or specialist. Primary care prescribers should not be asked to prescribe. Primary & Secondary Care Notes Secondary Care 5.1 Antibacterial drugs See Drug Colour Coding The empirical prescribing of antibacterial drugs should always be guided by local primary and secondary care guidelines. Do not use antibiotics unnecessarily. Use can predispose to colonisation/infection with resistant organisms or precipitate Clostridium difficile infection. See Antibacterial prescribing notes See also GWH Post-splenectomy antibiotic guidelines and associated GP letters. Selection of an antibiotic requires balancing its benefit against risk. Particular care should be taken in prescribing antibiotics in pregnancy, in renal or liver impairment and in the elderly. Consider individual allergic reactions. Patients who have had a life threatening reaction to penicillin should NOT be prescribed penicillins or cephalosporins. Advice on prescribing antibiotics in penicillin allergy can be obtained from Antibiotic prescribing in penicillin allergy. This formulary chapter contains those antimicrobial agents authorised for empirical use, and also those antibiotics restricted to use by microbiology recommedation in the 3T s clinical area. Agents not listed in this forumlary should not be prescribed for patients without discussion with local microbiologists and may require specific application and approval from the Trust or PCT. Intravenous antibiotics should be reviewed every 48 hours and changed to oral equivalents (where available) in a timely manner according to the local IV to oral intravenous switch policy. The following documents should be used in conjunction with this formulary when determining which antibacterial agents to prescribe: Primary care guidelines Secondary care guidelines and approved list As far as possible, the Trust guidelines avoid the use of cephalosporins, quinolones and other antibiotics suspected of contributing to Clostridium difficile infection. However it should be borne in mind that all antibiotics can contribute to Clostridium difficile infections and it is therefore important not to prescribe antibiotics unnecessarily or to extend courses without clinical justification Penicillins Phenoxymethylpenicillin oral Amoxicillin oral preparation For guidance on use of antibiotics and vaccinations for prophylaxis in asplenic patients, see trust guidelines. Amoxicillin injection Co-amoxiclav injection Flucloxacillin injection Flucloxacillin oral Piperacillin and tazobactam (Tazocin): only for neutropenic sepsis, severe HAP or sepsis of unknown origin in patients with renal impairment, as per GWH guidelines.

2 Chapter 5 page number 2 Co-amoxiclav oral Benzylpenicillin injection Benzathine benzylpenicllin injection May be first or second line, depending on indication and whether using in primary or secondary care please refer to guidelines Do not use combinations of antibiotics that cover similar organisms NB Co-amoxiclav and Metronidazole do not need to be routinely used together to cover anaerobic infections. First line in primary care for suspected meningococcal disease Only available as unlicensed preparation. Pivmecillinam ONLY for second-line treatment of UTI in patients whose microbiological cultures shows sensitivity to Pivmecillinam or in whom first-line options are contraindicated Cephalosporins and other beta-lactams Please note the following cephalosporins should ONLY be prescribed in line with Wiltshire, Swindon & BaNES Guidelines for Antibiotic Prescribing in the Community (primary care), Trust Antibiotic Guidelines (secondary care) or on the specific recommendations of a GWH Microbiologist. Cefalexin Ceftazidime Cefixime Cefotaxime Ceftriaxone Cefuroxime: NOT ROUTINELY STOCKED AT GWH Aztreonam : microbiological/paediatric consultant advice only. GWH Carbapenems Use is restricted within secondary care guidelines Ertapenem/ Meropenem: microbiology advice only Imipenem with cilastatin/ Doripenem microbiology advice only NOT ROUTINELY STOCKED AT GWH Tetracyclines Avoid in children youger than 12 years and in breastfeeding women deposition of tetracyclines in growing bones and teeth causes staining and dental hypoplasia. Doxycycline Oxytetracycline: see chapter Lymecycline: see chapter Demeclocycline see chapter Note second line choice for dermatology patients; see section Second line treatment for animal bites in penicillin allergy in primary care. Tigecycline: microbiology advice only.

3 Chapter 5 page number Aminoglycosides Gentamicin Tobramycin nebulised solution (Tobi): specialist prescribing. Colistimethate Colistimethate Macrolides Azithromycin Clarithromycin oral preps. Stat doses for insertion/removal of catheters. For information on gentamicin, framecitin, gramicidin and neomycin in topical ENT, see section 12.1 See MHRA Drug Safety Update Nov17 for further information and advice on the potential for histamine-related adverse drug reactions with some batches. See NICE TA276 For use in bronchiectasis and existing CF patients (usually nebulised). See NICE TA276 For use in new CF patients (usually nebulised). See NICE TA276 For treatment of Chlamydia trachomatis Azithromycin is available OTC post positive sample. For further information see: Available on PGD at participating pharmacies in Swindon PCT through Contraceptive and Sexual Health Service. Second line treatment of otitis media in primary care: if penicillin allergic. First line macrolide in primary care.first line treatment for Helicobacter pylori. Gentamicin once daily dosing except endocarditis,paediatric mennigitis patients or on microbiology recommendation. Refer to trust guidelines for information on therapeutic drug monitoring. See MHRA Drug Safety Update Nov17 for further information and advice on the potential for histamine-related adverse drug reactions with some batches. Gentamicin 0.3 % eye drops Gentamicin 1.5% eye drops preservative free see section Amikacin injection paediatric consultant/microbiology advice only. Monitoring of drug levels is required. Clarithromycin injection: only for use in severe community aquired pneumonia or as IV alternative to oral erythromycin. Erythromycin 0.5 % eye ointment (unlicensed) Treatment of suspected Chlamydia in Neonates. To be assessed by paediatricians. See Erythromycin oral Erythromycin topical : See section Azithromycin Clindamycin Clindamycin oral preps Clindamycin topical First line macrolide in secondary care Alternative in pregnancy to clarithromycin or as a second line treatment of Chlamydia in primary care. Erythromycin oral preparation for the treatment of acne: See section Specialist initiation only for treatment of bronchiectatics with recurrent Pseudomonas exacerbations. Treatment of cellulitis in penicillin allergic patients in primary care. See chapter Clindamycin injection and oral : microbiology advice only.

4 Chapter 5 page number Other antibacterials Chloramphenicol ophthalmic Fusidic acid/sodium fusidate topical Vancomycin oral (capsules) Fusidic acid oral preps Teicoplanin Chloramphenicol injection Fidaxomicin Rifaximin See section See section & 2 First line topically for impetigo only for small localised legions. Only for treatment of Clostridium difficile associated diarrhoea. Initiation on microbiology advice only. See MHRA safety alert on interactions with statins. Initiation in secondary care only as per guidelines. See GWH guidelines for dosing and therapeutic drug monitoring requirements Only for use in meningitis in severe penicillin allergy in primary care Epiglottitis and supraglottitis if penicillin allergic, or on microbiology advice. For use only on the advice of microbiology or the Clostridium difficile team For use in the prevention of recurrent episodes of hepatic encephalopathy ONLY on the advice of Consultant Liver Specialist / Consultant Gastroenterologist, in accordance with NICE TA 337. See 3Ts prescribing guidance on the treatment of hepatic encephalopathy for further advice on place in therapy. See also 3Ts SCA on Rifaximin for hepatic encephalopathy. Fusidic acid injection: On microbiologicay advice only. See MHRA safety alert on interactions with statins. Linezolid oral and infusion: microbiology advice only. Vancomycin injection: see GWH guidelines for dosing and therapeutic drug monitoring requirements Daptomycin Injection microbiology advice only. Quinupristin with Dalfopristin (Synercid) Injection microbiology advice only. Promixin For use in paediatrics only following initiation by specialist centre Fosfomycin IV For use on the recommendation of a Consultant Microbiologist only Sulphonamides and trimethoprim Trimethoprim oral Co-trimoxazole oral For prophylaxis of PJP (Pneumocystis carinii/ jiroveci pneumonia); see section Trimethoprim Inj: microbiology advice only. Cotrimoxazole injection: For treatment of PJP (Pneumocystis carinii/ jiroveci pneumonia) only. Sulphamethoxypyridazine unlicensed use in dermatology for blistering disease. 15% sulphacetamide in alcohol For use by specialist dermatologists only for nail infections.

5 Chapter 5 page number Antituberculosis drugs Rifampicin See GWH guidelines Antileprotic drugs All anti TB treatments will be under the direction of a respiratory consultant. For current guidance on treatment of tuberculosis, refer to NICE guidance CG33 (March 2006) For treatment of multi resistant TB seek advice from microbiology or GWH respiratory physician: Dr Onyirioha: hospital ext 6500/bleep Respiratory secretaries: hospital ext 4766/ Metronidazole and tinidazole Metronidazole oral See hospital guidelines for use in treatment of Clostridium difficile associated diarrhoea. For use in confirmed TB only under the direction of a respiratory consultant: Rifinah Rifater Pyrazinamide Isoniazid Ethambutol Other may be considered on specialist advice in MDR or XDR cases of TB. Dapsone: on microbiology advice. For use in dermatology or for treatment of PJP (see 5.4.8), on specialist advice only Clofazimine: For use in dermatology on specialist advice only. Metronidazole injection Metronidazole topical praparations: See section & 2 Tinidazole microbiology advice only. (see also 5.4.4) Quinolones Use is restricted within primary and secondary care guidelines. Ciprofloxacin 0.3% See formulary section 12.1 drops (Ciloxan ): Ciprofloxacin oral For use only in specific indications according to GWH guidelines, primary care guidelines, or on microbiology recommendation. Ofloxacin Use in primary care for treatment of PID or acute prostatitis only Urinary tract infections Nitrofurantoin Do not use in patients with a history of or with suspected renal failure. Please see MHRA Drug Safety Update August Now contraindicated in most patients with egfr of less than 45ml/min/1.73m2. Please see MHRA Drug Safety Update Sept Ciprofloxacin injection: Use to be restricted as per hospital antibiotic guidelines. Moxifloxacin Consultant ophthalmologist or microbiology advice only. GWH Fosfomycin For prescribing on the advice of consultant microbiologist only. Refer Fosfomycin Guidelines for details of prescribing and supply by community pharmacy in primary care. See NICE evidence summary for additional information.

6 Chapter 5 page number Antifungal Drugs Studies suggest that lipid-based amphotericin (Ambisome) is less nephrotoxic than conventional amphotericin. However liposomal amphotericin is significantly more expensive, and due to the paucity of randomised trials showing its efficacy against proven invasive disease its use is limited to: - haematology patients, or immunosuppressed patients - those requiring prolonged therapy. - Patients who have failed on conventional therapy (> 500mg conventional dose) - concomitant use of nephrotoxic agents. - those with pre-existing renal impairment (creatinine clearance < 60ml/min). - those with a rapidly rising or significant increase in creatinine or other signs of severe toxicity related to conventional amphotericin use. Secondary care treatment of invasive fungal infections is based on positive cultures and advice from microbiology and mycology from the reference laboratory in Bristol. Nystatin oral suspension Amphotericin injection Fluconazole oral Clotrimazole -pessaries -cream Itraconazole Posaconazole Miconazole (Daktarin oral gel) Primary care for vaginal candidiasis. secondary care for treatment and prophylaxis of oral candida. Use liquid preparation. Primary care: for nail infections. Secondary care initiated only: Prophylaxis in haematology patients. Caution in patients at high risk of heart failure. For prophylactic use only in haematology patients who cannot tolerate itraconazole. See MHRA Drug Safety Update Sept 16 for further safety information and advice. Available OTC See MHRA Drug Safety Update June 2016 for further information and advice on the potential for topical miconazole, including oral gel, to seriously interact with warfarin. See MHRA Drug Safety Update Sept 17 for information on the contraindication of over-thecounter miconazole oral gel in patients taking wafarin, and advice to healthcare professionals wishing to prescribe this combination. Fluconazole IV For serious systemic candida infections. Flucytosine On microbiology advice only. Micafungin Use ONLY in accordance with Trust antifungal guidelines or on the advice of a Consultant Microbiologist. Anidulafungin Use ONLY in accordance with Trust antifungal guidelines or on the advice of a Consultant Microbiologist. Caspofungin On microbiology advice only. Voriconazole on microbiology advice only. See MHRA Drug Safety Update for information on risk of liver toxicity, phototoxicity and squamous cell carcinoma for the skin. Terbinafine Amorolfine nail laquer For nail infections (see skin chapter ) For nail infections (see skin chapter )

7 Chapter 5 page number Antiviral Drugs HIV Infection refer to British HIV Guidelines at For information on drug interactions see the Liverpool University site at Nucleoside reverse transcriptase inhibitors Lamivudine Abacavir Didanosine (Videx ) Emtricitabine (Emtriva ) Stavudine Tenofovir Zidovudine Combination nucleoside reverse transcriptase inhibitors Zidovudine/Lamivudine Abacavir/Lamivudine Abacavir/Lamivudine/ Zidovudine (Trizivir ) Emtricitabine/ Tenofovir disoproxil fumarate (Truvada ) Emtricitabine/ Tenofovir alafenamide fumarate (Descovy ) Protease inhibitors Atazanavir Darunavir (Prezista ) Fosamprenovir (Telzir ) Indinavir Ritonavir See MHRA Drug Safety Update Dec 16 for further information and advice on risk of serious adverse effect. Saquinavir Tipranivir (Aptivus ) Combination protease inhibitors See MHRA Drug Safety Update Dec 16 for further information and advice on risk of serious adverse effect. Atazanavir/ Cobicistat (EvoTaz ) Darunavir /Cobicistat (Rezolsta ) Non-nucleoside reverse transcriptase inhibitors Lopinavir/Ritonavir (Kaletra )

8 Chapter 5 page number 8 Efavirenz Nevirapine Etravirine Rilpivirine

9 Chapter 5 page number 9 Combination nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors Efavirenz/Entricitabine/Tenofovir disoproxil fumarate (Atripla ) Emtricitabine/Rilpivirine /Tenofovir disoproxil fumarate (Eviplera ) Emtricitabine/Rilpivirine/ Tenofovir alafenamide fumarate (Odefsey ) Other antiretrovirals Maraviroc Raltegravir Dolutegravir (Tivicay ) Dolutegravir / Lamivudine (Triumeq ) Elvitegravir/ Emtricitabine/ Tenofovir alafenamide fumarate / Cobicistat (Genvoya ) See MHRA Drug Safety Update Dec 16 for further information and advice on risk of serious adverse effect Herpesvirus and varicella zoster infections Aciclovir Elvitegravir/ Emtricitabine/ Tenofovir disoproxil fumarate / Cobicistat (Stribild ) See MHRA Drug Safety Update Dec 16 for further information and advice on risk of serious adverse effect. Aciclovir IV Aciclovir 3% eye ointment See section Cytomegalovirus infection Treatment options will be based on virology and advice from Bristol Reference Laboratory Cidofovir injection Microbiology recommendation only. NOT ROUTINELY STOCKED AT GWH Ganciclovir injection Valganciclovir Microbiology recommendation only. NOT ROUTINELY STOCKED AT GWH Viral Hepatitis Foscarnet injection: Microbiology recommendation only. GWH

10 Chapter 5 page number Chronic Hepatitis B Treatment of viral hepatitis B is covered by NICE Clinical Guideline CG165 and NICE Technology Appraisals TA96, TA153, TA154 and TA173. Tenofovir ONLY for initiation by Consultant Gastroenterologist specialising in liver disease. Entecavir ONLY for initiation by Consultant Gastroenterologist specialising in liver disease. Interferon Alfa 2a ONLY for initiation by Consultant Gastroenterologist specialising in liver disease Chronic Hepatitis C Treatment of viral hepatitis C is covered by NICE Technology Appraisals: TA75, TA106, TA200, TA252, TA253, TA300, TA330, and TA331 Please see MHRA Drug Safety Update Jan 17 for further information and advice on risk of Hepatitis B reactivation and risk of interaction with Vitamin K antagonists. Please note prescribing for patients with chronic hepatitis C is via tertiary centres ONLY Influenza Refer to NICE Guidelines TA168 and HPA guidelines for use in epidemic or pandemic influenza outbreaks. Oseltamivir Give within 48 hours of onset of symptoms/exposure. Preferred drug in breast feeding. Use at GWH following pandemic influenza guidance. Zanamivir Give within 36 hours of onset of symptoms/ exposure. Preferred drug during pregnancy Respiratory syncytial virus Palivizumab On advice of consultant neonatologists only. Ribavirin Only after seeking microbiologist advice. GWH 5.4 Antiprotozoal Drugs Antimalarials Prophylactic agents including Proguanil hydrochloride with Atovaquone (Malarone ), Chloroquine, Mefloquine, Proguanil and Doxycycline are available on private prescriptions only. For advice on treatment of malaria, contact GWH microbiology or London Hospital for Tropical diseases on For advice on malarial prophyaxis, the following resources are available: (requires nhs login) Pharmacy Medicines Information (5029). Health Protection Agency Malaria World Health Organisation emims Travel Tables (requires user login) BNF advice on antimalarial prophylaxis. Mepacrine unlicensed use in dermatology. Quinine hydrochloride injection See MHRA Drug Safety Update Nov 17 for further information and advice on dose-dependent QTprolonging effects and updated medicine interactions.

11 Chapter 5 page number Amoebicides Diloxanide Furoate Prescribe if positive microscopy or serology. Metronidazole Antigiardial drugs Metronidazole Tinidazole Drugs for pneumocystis pneumonia Please refer to hospital treatment guidelines for Pneumocystis jirovecii (formerly carnii) Only after seeking microbiologist advice: Cotrimoxazole injection Clindamycin Primaquine Dapsone Trimethoprim Trimetrexate Atovaquone Pentamidine isetionate

12 Chapter 5 page number Anthelmintics Drugs for threadworms Mebendazole Recommended for all children >6 months and adults. Repeat in 2/52 if infestation persists. Piperazine Only use in children aged 3-6 months only Ascaricides seek microbiologist/dermatologist specialist advice Drugs for tapeworm infections seek microbiologist/dermatologist specialist advice Drugs for hookworms seek microbiologist/dermatologist specialist advice Schistosomicides seek microbiologist/dermatologist specialist advice Filaricides seek microbiologist/dermatologist specialist advice. Ivermectin Drugs for cutaneous larva migrans seek microbiologist/dermatologist specialist advice Drugs for strongyloidiasis seek microbiologist/dermatologist specialist advice. Albendazole References: Primary care - Wilts & Swindon Guidelines for Antibiotic Prescribing in the Community Secondary care - Acute Trust Antibiotic Prescribing Supporting individual antibiotic treatment guidelines are available on request. Contact GWH Antibiotic Team.

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and 5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs

More information

Chapter 5 ~ Infections

Chapter 5 ~ Infections Chapter 5 ~ Infections: Special Section 1 of 6 Chapter 5 ~ Infections Please refer to The Hillingdon Hospitals NHS Trust Antibiotic Guidelines, Policy number 233, and Surgical Prophylaxis Policy, Policy

More information

NHS Fife Antibiotic Guidance for the Treatment of Community Managed Infections

NHS Fife Antibiotic Guidance for the Treatment of Community Managed Infections 1 5. Infections Also see Primary Care and Hospital Antibiotic Guidance NHS Fife Antibiotic Guidance for the Treatment of Community Managed Infections Management of Serious Infections in Paediatrics. Guidance

More information

Report generated from BNF provided by FormularyComplete ( Accessed TA Number. Title Formulary Status Section

Report generated from BNF provided by FormularyComplete (  Accessed TA Number. Title Formulary Status Section Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ACICLOVIR Aciclovir 5.3 Antiviral drugs->5.3.2

More information

CEFACLOR Non Formulary 5.1 Antibacterial drugs->5.1.2 Cephalosporins, carbapenems, and other beta-lactams-> Cephalosporins

CEFACLOR Non Formulary 5.1 Antibacterial drugs->5.1.2 Cephalosporins, carbapenems, and other beta-lactams-> Cephalosporins Report generated from BNF - Local Information provided by FormularyComplete (www.pharmpress.com). Accessed 31 07 2017 Title Formulary Status Section Amikacin Non Formulary 5.1 Antibacterial drugs->5.1.4

More information

Inventory of paediatric therapeutic needs

Inventory of paediatric therapeutic needs 12 December 2012 EMA/PDCO/287222/2012 Human Medicines Development and Evaluation Infectious diseases Agreed by PDCO November 2012 Adopted by PDCO for release for consultation 7 December 2012 Start of public

More information

This letter authorises the extended use of the following guidance until 1st December 2018:

This letter authorises the extended use of the following guidance until 1st December 2018: NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date 29 1h May 2018 Our Ref FApenicillin/hype/MGPG/May 18 Enquiries to Frances Adamson Extension 56689 Direct Line 01224

More information

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir,

More information

B. Incorrect! Peginterferon α-2a is used for the treatment of chronic hepatitis B and may be preferable to interferon- α.

B. Incorrect! Peginterferon α-2a is used for the treatment of chronic hepatitis B and may be preferable to interferon- α. Pharmacology - Problem Drill 24: Antibiotics, Antifungal and Antiviral Drugs Question No. 1 of 10 1. reduces the replication of influenza A and B viruses by inhibiting viral neuraminidase. Question #01

More information

Both adult and pediatric* 24 (46% of 52 members) Region: New England 51 (48% of 107 members) 45 (52% of 87 members) 29 (47% of 62 members)

Both adult and pediatric* 24 (46% of 52 members) Region: New England 51 (48% of 107 members) 45 (52% of 87 members) 29 (47% of 62 members) Infectious Diseases Society of America Emerging Infections Network Report for Query: Antimicrobial Drug Shortages 2016 Overall response rate: 701/1,597 (44%) physicians responded from 3/22/16 to 4/13/16.

More information

Antiretroviral Dosing in Renal Impairment

Antiretroviral Dosing in Renal Impairment Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis

More information

Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Anti-Infective Subcommittee minutes for web publishing

Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Anti-Infective Subcommittee minutes for web publishing Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Anti-Infective Subcommittee minutes for web publishing Infections therapeutic group PTAC and Subcommittee of PTAC minutes are

More information

Drug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD

Drug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD Antimicrobial Dosing in Renal Insufficiency (Adults) ASP Handbook * In patients on hemodialysis (), give antimicrobial immediately after dialysis on dialysis days. = Intermittent hemodialysis = Peritoneal

More information

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir

More information

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/

More information

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS - 2014 Alabama s ADAP formulary offers a minimum of one medication from each HIV antiretroviral class approved by the U.S. Food and Drug Administration (FDA).

More information

MONTEFIORE MEDICAL CENTER

MONTEFIORE MEDICAL CENTER DEPARTMENT OF PHARMACY MONTEFIORE MEDICAL CENTER SUBJECT: MANUAL CODE: Restricted Drugs Policy, Antibiotic Restriction PH-R-5 DATE ISSUED: August, 1976 DATE REVISED: September 2000, October 2003, September

More information

Antimicrobial Management of Febrile Neutropenic Sepsis

Antimicrobial Management of Febrile Neutropenic Sepsis Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:

More information

HIV Drugs and the HIV Lifecycle

HIV Drugs and the HIV Lifecycle HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's

More information

104 MMWR December 17, 2004

104 MMWR December 17, 2004 104 MMWR December 17, 2004 TABLE 8. Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic Drugs Interacting with Mechanism/effects Recommendations Acyclovir

More information

gram neg.(semisynthetic) Bacteria Drugs that inhibit cell wall synthesis Drug Action Organisms Comments Spectrum of Action Mycobacterium

gram neg.(semisynthetic) Bacteria Drugs that inhibit cell wall synthesis Drug Action Organisms Comments Spectrum of Action Mycobacterium Mickey Dufilho s Drugs and Bugs Revised 10/10/15 Bacteria Drugs that Inhibit Cell Wall Synthesis Drug Action Spectrum of Action Comments Spectrum of Action Bacitracin Beta-Lactam antibiotics Penicillin

More information

Appropriate Use & Safety Edits

Appropriate Use & Safety Edits Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely

More information

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg. AMIKACIN All ages>1month: 30mg/kg daily 1.5g once daily IV infusion over 30-60 Monitor renal function before treatment and weekly. Caution if used with other nephrotoxic drugs. Levels required. Trough

More information

Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters

Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline

More information

treatment passport 1

treatment passport 1 treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor

More information

Neutropenic Sepsis Guideline

Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline - definitions Suspected or proven infection in a neutropenic patient is a MEDICAL EMERGENCY and is an indication for immediate assessment and prompt

More information

Antimicrobial Reference Laboratory

Antimicrobial Reference Laboratory Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2016-17 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB UK Aminoglycosides Gentamicin

More information

1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017

1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017 To support national and global efforts to increase access to and the affordability of care and treatment of HIV/AIDS, hepatitis B and C, tuberculosis, malaria, neglected tropical diseases, influenza, diarrhoea

More information

Drug Treatment Program Update

Drug Treatment Program Update Drug Treatment Program Update As of March 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential

More information

Malaria prevention: source = The Sanford Guide to Antimicrobial Therapy. Gilbert et al.

Malaria prevention: source = The Sanford Guide to Antimicrobial Therapy. Gilbert et al. Malaria prevention: Agent Adult dose a Contraindications Application Notes Atovaquoneproguanil 250/100mg x1/day Insufficient data in pregnancy Prophylaxis for areas with CQ resistance, 2 expensive with

More information

Antibiotic Guidelines for URINARY TRACT/ UROLOGY infections

Antibiotic Guidelines for URINARY TRACT/ UROLOGY infections Antibiotic Guidelines f URINARY TRACT/ UROLOGY infections CLINICAL CONDITION USEFUL INFORMATION RECOMMENDATIONS ALTERNATIVE (suitable in serious penicillin allergy) Asymptomatic Bacteriuria (in the absence

More information

Simplifying HIV Treatment Now and in the Future

Simplifying HIV Treatment Now and in the Future Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line

More information

2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California

2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California 2015 OPSC Annual Convention syllabus February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California SUNDAY, FEBRUARY 8, 2015: 10:00am - 11:00am Primary Care of the HIV Patient Presented by Jim Lee,

More information

HIV Treatment Guidelines

HIV Treatment Guidelines HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based

More information

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman

More information

CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs

CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines

More information

ANTIRETROVIRAL TREATMENTS (Part 1of

ANTIRETROVIRAL TREATMENTS (Part 1of CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after

More information

Lifting the lid on a difficile problem part 2 (Clinical) Evidence Based Practice. Problem in evolution (1) Problem in evolution (1) Interventions (2)

Lifting the lid on a difficile problem part 2 (Clinical) Evidence Based Practice. Problem in evolution (1) Problem in evolution (1) Interventions (2) Lifting the lid on a difficile problem part (Clinical) Dr Philip T Mannion Consultant Microbiologist, Rhyl Evidence Based Practice Antibiotic prescribing guidance Isolation policy Hand hygiene (soap and

More information

OPAT DATA MANAGEMENT: AN OVERVIEW OF NORS & THE OPAT SERVICE DIRECTORY. BSAC OPAT REGIONAL WORKSHOP London 14 May 2018

OPAT DATA MANAGEMENT: AN OVERVIEW OF NORS & THE OPAT SERVICE DIRECTORY. BSAC OPAT REGIONAL WORKSHOP London 14 May 2018 OPAT DATA MANAGEMENT: AN OVERVIEW OF NORS & THE OPAT SERVICE DIRECTORY BSAC OPAT REGIONAL WORKSHOP London 14 May 2018 Presented by Felicity Drummond Senior Project Manager, BSAC NORS provides the most

More information

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core

More information

The Child with HIV and a Fever 1

The Child with HIV and a Fever 1 The Child with HIV and a Fever 1 Author: Andrew Riordan Amanda Williams Date of preparation: August 2003 Date reviewed: February 2012 Next review date: February 2014 Contents 1. Introduction 2. HIV disease

More information

HIV Management Update 2015

HIV Management Update 2015 9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe

More information

Antimicrobial Reference Laboratory

Antimicrobial Reference Laboratory Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2018 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB Guideline Ranges 2018 Aminoglycosides

More information

ANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS

ANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS ANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS Version 4.0 Date ratified February 2009 Review date February 2011 Ratified by Authors Consultation Evidence

More information

GUIDELINES FOR USERS ANTIMICROBIAL REFERENCE LABORATORY ASSAY SERVICE. 17th Edition

GUIDELINES FOR USERS ANTIMICROBIAL REFERENCE LABORATORY ASSAY SERVICE. 17th Edition ANTIMICROBIAL REFERENCE LABORATORY ASSAY SERVICE GUIDELINES FOR USERS 17th Edition 2011 Earlier editions should be destroyed Antimicrobial Reference Laboratory Department of Medical Microbiology North

More information

Monographs on ARV and hepatitis medicines in The International Pharmacopoeia

Monographs on ARV and hepatitis medicines in The International Pharmacopoeia Monographs on ARV and hepatitis medicines in The International Pharmacopoeia Technologies, Standards and Norms 1 The International Pharmacopoeia contains analytical methods and specifications for active

More information

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and

More information

Medication Errors Focus on the HIV-Infected Patient

Medication Errors Focus on the HIV-Infected Patient Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation

More information

I is a cascading prodrug. II is used to treat hepatitis B infection III ultimately inhibits viral reverse transcriptase.

I is a cascading prodrug. II is used to treat hepatitis B infection III ultimately inhibits viral reverse transcriptase. Medicinal Chemistry 410 Exam #1 February 19, 2010 ame: Med. Chem. # 1 Part. (75 Points) There are 50 multiple choice questions worth 1.5 points each (75 Points). Please use the cantron heet provided. f

More information

Antibiotic Class Interacting Drug Comment Penicillins e.g. Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin

Antibiotic Class Interacting Drug Comment Penicillins e.g. Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin Antibiotic Class Interacting Drug Comment Penicillins Methotrexate Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin Cephalosporins Cefaclor Cefixime Cefuroxime Cephalexin Cefazolin* Ceftriaxone*

More information

OPAT Community and Outcomes: The OPAT Service Directory and National Outcomes Registry

OPAT Community and Outcomes: The OPAT Service Directory and National Outcomes Registry OPAT Community and Outcomes: The OPAT Service Directory and National Outcomes Registry For enquiries/support: Service Directory in Action! Can BSAC sort out daily antibiotics? GP R OPAT Community and

More information

Title: Author: Speciality / Division: Directorate:

Title: Author: Speciality / Division: Directorate: Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality

More information

Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016

Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016 Adult Inpatient Antibiogram Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates January to December 2016 Department of Pathology Camille Hamula, PhD Director, Clinical Microbiology

More information

Fraser Health pandemic preparedness

Fraser Health pandemic preparedness Fraser Health pandemic preparedness DRAFT Last revised: April 2006 General Management of Patients in Acute Care Facilities During an Influenza Pandemic 1. OVERVIEW GENERAL MANAGEMENT OF PATIENTS IN ACUTE

More information

2019 PHP PRIMARY CARE INCENTIVE

2019 PHP PRIMARY CARE INCENTIVE Primary Care Physicians (PCP) of Physicians Health Network (PHN) may be eligible for an incentive payment in accordance with this PHP PCP Incentive (hereinafter referred to as the PCP Incentive ). As described

More information

Community Pharmacy Support Guidance: Electronic Repeat Dispensing (erd)

Community Pharmacy Support Guidance: Electronic Repeat Dispensing (erd) Community Pharmacy Support Guidance: Electronic Repeat Dispensing (erd) Version: 2.1 Date Published October 2018 Author: Rachel Raybould, Midland and Lancashire CSU 1 Introduction: Welcome to the Community

More information

Antiretrovial Crushable/Liquid Formulation Chart

Antiretrovial Crushable/Liquid Formulation Chart Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in

More information

Sculpting a Better Regimen: The ART of HIV Medications

Sculpting a Better Regimen: The ART of HIV Medications Sculpting a Better Regimen: The ART of HIV Medications Kelly Peddy, PharmD, MPA Clinical Pharmacy Specialist - Ambulatory Care Memorial Hospital of South Bend November 30, 2017 For HealthTrust Members

More information

5 - Infections. In alphabetical order Product Manufacturer. NHS Lothian decision. Date of NHS Lothian decision. Condition being treated

5 - Infections. In alphabetical order Product Manufacturer. NHS Lothian decision. Date of NHS Lothian decision. Condition being treated Recommendations from the Lothian Formulary Committee (FC) following Scottish Medicines Consortium (SMC) advice, NICE MTA advice, (FAF3) unlicensed and off-label medicines and (FAF2) medicines not considered

More information

1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016

1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016 To support national and global efforts to increase access to and the affordability of HIV/AIDS-related care and treatment together with UNICEF, UNAIDS and UNITAID, invite applicants for selected pharmaceutical

More information

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none

More information

POLICY FOR TREATMENT OF UPPER RESPIRATORY TRACT INFECTIONS

POLICY FOR TREATMENT OF UPPER RESPIRATORY TRACT INFECTIONS POLICY F TREATMENT OF UPPER RESPIRATY TRACT INFECTIONS Written by: Dr M Milupi, Consultant Microbiologist Date: July 2013 Approved by: The Drugs & Therapeutics Committee Date: April 2016 Implementation

More information

LRI Children s Hospital

LRI Children s Hospital Title: Prescribing in Cystic Fibrosis Page 1 of 10 LRI Children s Hospital Prescribing in Cystic Fibrosis Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team & AWP approval

More information

December 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide

December 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide Severe Sepsis and Septic Shock Antibiotic Guide Surviving Sepsis: The choice of empirical antimicrobial therapy depends on complex issues related to the patient s history, including drug intolerances,

More information

If these vaccines haven t been given, please follow guidelines below for emergency procedures.

If these vaccines haven t been given, please follow guidelines below for emergency procedures. MANAGEMENT OF PATIIENTS POST SPLENECTOMY & HYPOSPLENIIC PATIIENTS Splenectomised and hyposplenic patients are at increased risk of life-threatening infections due to encapsulated micro-organisms such as

More information

Exploring HIV in 2017: What a pharmacist needs to know

Exploring HIV in 2017: What a pharmacist needs to know Exploring HIV in 2017: What a pharmacist needs to know Lifecycle of the HIV virus a. HIV spread through mucous membrane contact, damaged tissue contact, or blood contact with: blood, semen, rectal fluids,

More information

ADULT ANTIMICROBIAL DOSING TOOL (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017)

ADULT ANTIMICROBIAL DOSING TOOL (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017) (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017) Introduction The dosing recommendations presented here are for adults with moderate-to-severe infections and are

More information

Infection. Chapter 5 TABLE OF CONTENTS

Infection. Chapter 5 TABLE OF CONTENTS Chapter 5 Infection TABLE OF CONTENTS Table of Contents... 1 1 Antibacterial Drugs... 2 1.1 Before starting therapy... 2 1.1.1 Pregnancy... 2 1.1.2 Renal impairment... 2 1.2 Aminoglycosides... 2 1.2.1

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A AAP. See American Academy of Pediatrics (AAP) Acyclovir dosing in infants, 185 187 American Academy of Pediatrics (AAP) COFN of, 199 204 Amphotericin

More information

CANDIDIASIS (WOMEN) Single Episode. Clinical Features. Diagnosis. Management

CANDIDIASIS (WOMEN) Single Episode. Clinical Features. Diagnosis. Management CANDIDIASIS (WOMEN) What s new: Section on Management of Vulvovaginal Non-Albicans Candida Infection in Adults approved by GGC antimicrobial team Routine candida sensitivity testing has been discontinued,

More information

FORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary

FORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary At a Glance: VA ADAP Formulary Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Multi Class Combination Agents Protease Inhibitors

More information

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)

More information

Selecting an Initial Antiretroviral Therapy (ART) Regimen

Selecting an Initial Antiretroviral Therapy (ART) Regimen Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,

More information

Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents

Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in

More information

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf Risk of HIV-1 low level viremia to treatment failure in the AREVIR-RESINA cohort in Germany Nadine Lübke Düsseldorf FDA Approval of antiretroviral drugs 1980-84 1985-89 1990-94 1995-99 2000-04 2005-09

More information

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: TACROLIMUS Protocol number: CV 43

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: TACROLIMUS Protocol number: CV 43 Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: TACROLIMUS Protocol number: CV 43 Indications: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION IN ADULTS.

More information

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: CICLOSPORIN Protocol number: CV 06

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: CICLOSPORIN Protocol number: CV 06 Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: CICLOSPORIN Protocol number: CV 06 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION IN ADULTS

More information

Appendix 4: Renal impairment

Appendix 4: Renal impairment Appendix 4: Renal impairment Reduced renal function may cause problems with drug therapy for the following reasons: 1. The failure to excrete a drug or its metabolites may produce toxicity. 2. The to some

More information

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take

More information

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications. Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically

More information

Amy-Jo Hooley Specialist Clinical Pharmacist

Amy-Jo Hooley Specialist Clinical Pharmacist Gut Decontamination Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Guideline for the Safe Administration

More information

Chapter 8 Malignant Disease and Immunosuppression

Chapter 8 Malignant Disease and Immunosuppression Chapter 8 page number 1 Chapter 8 Malignant Disease and Immunosuppression First line drugs Drugs recommended in both primary and secondary care Second line drugs Alternatives (often in specific conditions)

More information

WESTERN CAPE ART GUIDELINES PRESENTATION 2013

WESTERN CAPE ART GUIDELINES PRESENTATION 2013 WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory

More information

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /

More information

POLICY FOR TREATMENT OF UPPER RESPIRATORY TRACT INFECTIONS

POLICY FOR TREATMENT OF UPPER RESPIRATORY TRACT INFECTIONS POLICY F TREATMENT OF UPPER RESPIRATY TRACT INFECTIONS Written by: Dr M Milupi, Consultant Microbiologist Date: June 2018 Approved by: Date: July 2018 The Drugs & Therapeutics Committee Implementation

More information

Supplementary Data. Supplementary Table S2. Antiretroviral Therapies Taken with Ledipasvir/Sofosbuvir

Supplementary Data. Supplementary Table S2. Antiretroviral Therapies Taken with Ledipasvir/Sofosbuvir Supplementary Data Statistical Analysis Due to the limited number of patients with acute kidney injury and concern for model overfitting, covariates included in multivariable logistic regression analyses

More information

PACKAGE INSERT FOR MYCOBUTIN

PACKAGE INSERT FOR MYCOBUTIN SCHEDULING STATUS: S4 PACKAGE INSERT FOR MYCOBUTIN PROPRIETARY NAME (AND DOSAGE FORM): MYCOBUTIN (Capsules) COMPOSITION: Each capsule contains 150 mg rifabutin. The other ingredients are microcrystalline

More information

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University

More information

The ART of Antiretroviral Therapy in Critically-ill Patients with HIV

The ART of Antiretroviral Therapy in Critically-ill Patients with HIV The ART of Antiretroviral Therapy in Critically-ill Patients with HIV Tyler Finocchio, PharmD, BCPS PGY2 Critical Care Pharmacy Resident Avera McKennan Hospital & University Health Center February 10 th,

More information

CHAPTER ONE: EXECUTIVE SUMMARY

CHAPTER ONE: EXECUTIVE SUMMARY CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

More information

Antibiotic guideline in Adult Cystic Fibrosis

Antibiotic guideline in Adult Cystic Fibrosis Adapted f Use in NHS Tayside January 2015 Antibiotic guideline in Adult Cystic Fibrosis Choice of antibiotics in cystic fibrosis is based on several facts including ganism sensitivity, histy of adverse

More information

PRAC recommendations on signals

PRAC recommendations on signals 3 April 2018 1 EMA/PRAC/136563/2018 Pharmacovigilance Risk Assessment Committee (PRAC) Adopted at the 5-8 March 2018 PRAC meeting This document provides an overview of the recommendations adopted by the

More information

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)

More information

Critical Time Medication Procedure

Critical Time Medication Procedure Ref:PharmMM74 Critical Time Medication Procedure INITIATED BY: APPROVED BY: DATE APPROVED: Suzanne Scott-Thomas, Amanda Halloway Endorsed by Medication Safety Committee Sept 2011 VERSION: 1.1 OPERATIONAL

More information

Odefsey. (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow

Odefsey. (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow Introduction Brand name: Odefsey Generic name: Emtricitabine, rilpivirine, tenofovir alafenamide (TAF) Pharmacological

More information

Antibiotic Dosing in the Elderly

Antibiotic Dosing in the Elderly Antibiotic Dosing in the Elderly Philip Chung, PharmD, MS, BCPS Nebraska ASAP Community Network Pharmacy Coordinator Nebraska Medicine Disclosure I have no relevant disclosure The presentation includes

More information

VIII Updating Course of Antimicrobials and Infectious Diseases 2018

VIII Updating Course of Antimicrobials and Infectious Diseases 2018 The Author 2018. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).

More information